{
    "organizations": [],
    "uuid": "d88ef68d853bb684ae53f9c0077facb0ad309932",
    "author": "",
    "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-announces/brief-portola-pharmaceuticals-announces-results-of-chmp-oral-explanations-for-andexanet-alfa-and-betrixaban-idUSFWN1QA12S",
    "ord_in_thread": 0,
    "title": "BRIEF-Portola Pharmaceuticals Announces Results Of CHMP Oral Explanations For Andexanet Alfa And Betrixaban",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Portola Pharmaceuticals Inc:\n* PORTOLA PHARMACEUTICALS ANNOUNCES RESULTS OF CHMP ORAL EXPLANATIONS FOR ANDEXANET ALFA AND BETRIXABAN\n* PORTOLA PHARMA SAYS COMMITTEE FOR CHMP OF EMA COMMUNICATED POSITIVE TREND VOTE ON MARKETING AUTHORISATION APPLICATION FOR ANDEXANET ALFA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T23:51:00.000+02:00",
    "crawled": "2018-02-21T00:13:50.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "portola",
        "pharmaceutical",
        "inc",
        "portola",
        "pharmaceutical",
        "announces",
        "result",
        "chmp",
        "oral",
        "explanation",
        "andexanet",
        "alfa",
        "betrixaban",
        "portola",
        "pharma",
        "say",
        "committee",
        "chmp",
        "ema",
        "communicated",
        "positive",
        "trend",
        "vote",
        "marketing",
        "authorisation",
        "application",
        "andexanet",
        "alfa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}